Results 71 to 80 of about 1,213 (150)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model

Frontiers in Pharmacology, 2014
Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin and canagliflozin, have already been approved for use in USA and Europe; several ...
Oleg eDemin Jr, Tatiana eYakovleva, Dmitry eKolobkov, Oleg eDemin   +3 more
doaj   +1 more source

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Journal of Pharmacological Sciences, 2016
The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki   +4 more
doaj   +1 more source

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice

Journal of Pharmacological Sciences, 2016
Previously we investigated the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan using normal and diabetic mice.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki   +4 more
doaj   +1 more source

Issue Information

Journal of Diabetes Investigation, Volume 17, Issue 4, Page 553-556, April 2026.
wiley   +1 more source

Nocturia and SGLT2 inhibitors: A review of pathophysiology, clinical evidence, and therapeutic implications

Continence
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in patients with diabetes, heart failure, and chronic kidney disease, all of whom are at elevated risk for nocturia.
Matthew Antonellis, Robert Adler, Michael Kozlov, Jason Lazar, Jeffrey P. Weiss   +4 more
doaj   +1 more source

Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis

Journal of Diabetes Research
Background. Beyond glycemic control, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been proposed to reduce the risk of cardiovascular events.
Abolfazl Akbari, Shiva Hadizadeh, Leida Heidary   +2 more
doaj   +1 more source

Bullous Pemphigoid Following IgG/IgA Pemphigus: Possible Involvement of SGLT2 and DPP-4 Inhibitors. [PDF]

Acta Derm Venereol
Ikeda A, Tani N, Ishii N, Koga H, Yoshida Y.   +4 more
europepmc   +1 more source

Progranulin Deficiency Improves Metabolic Stress Yet Falls Short of Sodium-Glucose Cotransporter-2 Inhibition in Autophagy-Linked Renal Protection. [PDF]

Endocrinol Metab (Seoul)
Im SS.
europepmc   +1 more source

Effect of Tofogliflozin on Urinary Albumin-to-Creatinine Ratio vs. Metformin in Diabetic Kidney Disease: Rationale and Study Protocol of the TRUTH-DKD Trial. [PDF]

Diabetes Ther
Kimura K, Takagi Y, Harada M, Ueda S, Minamisawa M, Sonoda K, Oiwa A, Yazaki Y, Sakurai S, Tomita T, Kaneko K, Yamamoto K, Takama N, Momose S, Inobe Y, Nogi K, Koshikawa M, Misawa T, Kasai T, Tsutsui H, Watanabe N, Yamazaki K, Miyamoto T, Midorikawa T, Usui T, Saigusa T, Motoki H, Saito Y, Kamijo Y, Komatsu M, Kuwahara K.   +30 more
europepmc   +1 more source

Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin

Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin
学位の種別: 論文博士 審査委員会委員 : (主査)東京大学教授 九郎丸 正道, 東京大学教授 中山 裕之, 東京大学教授 久和 茂, 東京大学准教授 堀 正敏, 東京大学准教授 金井 ...
openaire